RT Journal Article
SR Electronic
T1 Sensitivity of commercial Anti-SARS-CoV-2 serological assays in a high-prevalence setting
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.11.20128686
DO 10.1101/2020.06.11.20128686
A1 Müller, Lisa
A1 Ostermann, Philipp N.
A1 Walker, Andreas
A1 Wienemann, Tobias
A1 Mertens, Alexander
A1 Adams, Ortwin
A1 Andree, Marcel
A1 Hauka, Sandra
A1 Keitel, Verena
A1 Drexler, Ingo
A1 Di Cristanziano, Veronica
A1 Hermsen, Derik Franz
A1 Kaiser, Rolf
A1 Boege, Friedrich
A1 Klein, Florian
A1 Schaal, Heiner
A1 Timm, Jörg
A1 Senff, Tina
YR 2020
UL http://medrxiv.org/content/early/2020/06/12/2020.06.11.20128686.abstract
AB We analysed SARS-CoV-2 specific antibody responses in 42 social and working contacts of a super-spreader from the Heinsberg area in Germany. Consistent with a high-prevalence setting 26 individuals had SARS-CoV-2 antibodies determined by in-house neutralisation testing. These results were compared with four commercial assays, suggesting limited sensitivity of the assays in such a high-prevalence setting. Although SARS-CoV-2 nucleocapsid-restricted tests showed a better sensitivity, spike-based assays had a stronger correlation with neutralisation capacity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Juergen Manchot Foundation and the Heinz-Ansmann foundation for AIDS research, Duesseldorf.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethics committee (study number: 5350).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.